Sign In
Buy AVIR
$4.70
-0.0400 (-0.84%)
At Close: Jul 31, 2026
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
06:55pm, Thursday, 05'th Mar 2026
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Thursday, 05'th Mar 2026
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Ou
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
07:00am, Thursday, 26'th Feb 2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral
Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceu
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR
04:22am, Monday, 23'rd Feb 2026
BML Capital Management LLC lessened its holdings in shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Ex
Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:55pm, Thursday, 15'th Jan 2026
Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 08'th Jan 2026
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 06'th Jan 2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened
01:33am, Wednesday, 31'st Dec 2025
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR - Get Free Report) was down 1.4% during mid-day trading on Tuesday. The company traded as low as $3.52 and last traded at $3.55. Approximately 251,688 shares w
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast
02:14am, Sunday, 28'th Dec 2025
Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) and Rapt Therapeutics (NASDAQ: RAPT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the tw
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026
05:51am, Tuesday, 23'rd Dec 2025
Atea Pharmaceuticals (AVIR) offers a late-stage, best-in-class HCV cure, with significant upside, currently trading below cash. BEM/RZR combines advantages of current first-line HCV therapies — sing
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside N
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
07:00am, Wednesday, 19'th Nov 2025
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiv
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript
02:31pm, Thursday, 13'th Nov 2025
Atea Pharmaceuticals, Inc. ( AVIR ) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Company Participants Jean-Pierre Sommadossi -
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript
07:01pm, Wednesday, 12'th Nov 2025
Atea Pharmaceuticals, Inc. ( AVIR ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-
